Clinical Trial Update: A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003) [Phase 2]

View source ↗

Summary

Phase 2 study to determine the optimal dose of tildrakizumab for moderate-to-severe chronic plaque psoriasis completed with posted results in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis

Drugs mentioned

• Ilumya (tildrakizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2015-03-30